Board summary
Key figures
28,872
Registered population
61.3% aged 18–64
16.8%
Aged 65+
ICB 18.8% · England 17.9%
17.6%
Ethnic minority (non-White)
8.7% Asian · England 9.6%
0.8%
In IMD quintile 1
ICB 0.8% · England 21.0%
~143
Core20 residents (est.)
Resident basis; registered basis ~166 · see page 3
3,931
Hypertension register
+3.95% in 3 yrs · England +5.60%
273
SMI register
23.7% of Reigate and Banstead's
374
COPD register
Reviews -17.71% in 3 yrs
Forecast to 2030
4,316
Hypertension patients, 2030
+385 on today
68.3%
QRISK ≥20% on statins, 2030
+2.44pp over 3 yrs
4.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Patients with Asthma: review in the last 12.
Patients with Asthma: review in the last 12 months is -24.0% over three years, worse than England.
Patients with COPD who had a review in.
Patients with COPD who had a review in the last 12 months is -17.7% over three years, worse than England.
IFCC-HbA1c <= 58 mmol/mol in patients with diabetes.
IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty is -3.6% over three years, worse than England.
Population, age and ethnicity
Population, age and ethnicity
Asian / Asian British is 8.7% at PCN level, above Reigate and Banstead (7.5%), above NHS Surrey Heartlands Integrated Care Board (7.7%) and below England (9.6%). This is above the comparator, which may reflect need or recording; check which before changing capacity.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Reigate and Banstead local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Reigate and Banstead LA) | 2,154 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Reigate and Banstead LA) | 991 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Reigate and Banstead LA) | 8.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation and Core20
Core20 cohort (IMD quintile 1) is 0.8% at PCN level, below Reigate and Banstead (1.1%), in line with NHS Surrey Heartlands Integrated Care Board (0.8%) and below England (21.0%). This is below the comparator, which may reflect need or recording; check which before changing capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
273
SMI register
0.92% recorded prevalence
231
Learning disability register
0.78% recorded prevalence
26
Care homes, 633 beds
In the PCN catchment
7.9%
Provide unpaid care
Reigate and Banstead, Census 2021
Severe mental illness register (patients) is 273 at PCN level. No comparator was captured, so this is context only; add a benchmark before choosing a response.
Severe mental illness: physical health checks
SMI register with a BP check in the last 12 months is 78.8% at PCN level, below Reigate and Banstead (84.0%), below NHS Surrey Heartlands Integrated Care Board (83.5%) and below England (83.4%). Fewer people with SMI have their physical-health checks recorded than the comparator, so closing this gap is a clear priority for the register.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
3,931
Hypertension register
+3.95%
Register growth, 3 yrs
Reigate and Banstead +4.55% · England +5.60%
−0.88pp
BP control, under 80
≤140/90 · +3.68pp aged 80+
+385
More patients by 2030
Forecast 4,316 (14.29%)
Hypertension case-finding and control
Hypertension: QOF prevalence is 13.2% at PCN level, below Reigate and Banstead (14.0%), below NHS Surrey Heartlands Integrated Care Board (14.3%) and below England (15.2%). Recorded hypertension is lower than the comparator, which may reflect a younger population or under-detection; a case-finding check is the first step.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy is 63.1% at PCN level, above Reigate and Banstead (59.3%), above NHS Surrey Heartlands Integrated Care Board (59.4%) and below England (63.6%). Lipid-lowering coverage is above the comparator, so the priority is keeping reach and reviewing who remains untreated.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 35,570 | £2.20 | £2.24 | £1.86 | £78,254 |
| Cardiovascular (all), 2025 | 54,700 | £3.91 | £4.74 | £3.33 | £213,877 |
Cost per item for Cholesterol/Hyperlipidemia 2025 is £2.18 at PCN level, above Reigate and Banstead (£2.11), in line with NHS Surrey Heartlands Integrated Care Board (£2.18) and above England (£1.82). Unit cost per item is above the comparator; check product mix and formulary before drawing any conclusion on value.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−24.04%
Asthma reviews, PCN 3-yr change
+4.44%
Asthma reviews, England
−2.30%
Asthma prevalence, PCN
Patients with Asthma: review in the last 12 months (denominator incl. PCAs) is 51.2% at PCN level, below Reigate and Banstead (59.8%), below NHS Surrey Heartlands Integrated Care Board (65.6%) and below England (65.7%). Respiratory review coverage is below the comparator, so reviews for this group are the practical place to start.
Cancer register and children's immunisation
Cancer: QOF prevalence (all ages) is 3.5% at PCN level, below Reigate and Banstead (4.3%), below NHS Surrey Heartlands Integrated Care Board (4.5%) and below England (3.8%). This is below the comparator, which may reflect need or recording; check which before changing capacity.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
Breast screening coverage: aged 53 to 70 years old is 77.5% at PCN level, above Reigate and Banstead (74.6%), above NHS Surrey Heartlands Integrated Care Board (71.2%) and above England (69.9%). Screening coverage is above the comparator; sustain it and check which groups are still missed.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
| Pathways within standard (%) | Surrey and Sussex Healthcare | Epsom and St Helier | Croydon Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 89.70 | 83.22 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 99.16 | 99.06 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 86.82 | 69.88 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Epsom and St Helier | Croydon Health | England |
|---|---|---|---|---|
| MRI | 27.53 | 0.31 | 0.26 | 21.40 |
| CT | 18.49 | 1.06 | 7.69 | 9.92 |
| Echocardiography | 43.78 | 25.49 | 3.60 | 28.48 |
| Colonoscopy | 15.11 | 33.01 | 21.80 | 30.83 |
| Gastroscopy | 21.06 | 30.90 | 17.94 | 29.02 |
| All 15 DM01 tests | 28.50 | 6.83 | 3.51 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Holmhurst | 108 | 1.6 | 56.9% | 76.5% | 87.8% |
| Hawthorns Surgery | 117 | 0.0 | 64.7% | 67.9% | 85.3% |
| Woodlands Road | 116 | 0.0 | 79.5% | 82.8% | 83.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Where the PCN lags
Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) (3-year % change) is +2.5% at PCN level, below Reigate and Banstead (+4.2%), above NHS Surrey Heartlands Integrated Care Board (+0.7%) and below England (+8.7%). This is worse than the comparator, so closing the gap is the priority for this measure.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD reviews
Learning disability register
Diabetes HbA1c control
Hypertension treated to target
Cervical screening
BP control, 80+
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Reigate and Banstead | Asset | PCN | Reigate and Banstead |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (633 beds) | n/a | Schools (catchment) | 60 | n/a |
| Children's centres | 5 | 8 | Places of worship | 36 | 70 |
| Libraries | 3 | 6 | Food banks (VCS) | 4 | 6 |
| Homelessness support (VCS) | 1 | 2 | Day centres (VCS) | 23 | 40 |
| Children and young people (VCS) | 7 | 8 | Carers support groups (VCS) | 6 | 6 |
| Primary schools (LA maintained) | 5 | 14 | Primary academies | 9 | 18 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
